Search DTIL
PRECISION BIOSCIENCES INC
Nasdaq · CIK 1357874
Last close6.31
Daily change-0.02 (-0.32%)
10 Years gain-98.79%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
DTIL · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 0521
Fundamental
44.2Momentum
0.0Acceleration
0.0Confidence
81.0Annual Revenue8
Quarterly Revenue26
Annual CFO8
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth8.4 / 25
Quality8.6 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics10.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
Operating margin compression · MEDIUMOperating margin compressed by 616.8009 percentage points.
Heavy share dilution · HIGHDiluted share count increased 178.2657%.
Key Metrics
Revenue Growth TTM-84.04%OK
Revenue CAGR 3Y10.93%OK
Gross Margin100%OK
Operating Margin-651.21%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-1,579.33%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y178.27%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $34.26M | $34.26M | -$52.15M | -$65.84M | -$65.93M | 100% | -152.19% | -192.41% | n/a | 12.83M |
| 2025 FY Dec 31, 2024 | $68.70M | $68.70M | -$26.16M | -$58.45M | -$58.70M | 100% | -38.08% | -85.44% | n/a | 6.88M |
| 2024 FY Dec 31, 2023 | $48.73M | $48.73M | -$43.74M | -$84.11M | -$86.07M | 100% | -89.76% | -176.64% | n/a | 3.84M |
| 2023 FY Dec 31, 2022 | $25.10M | $25.10M | -$62.31M | -$45.75M | -$49.07M | 100% | -248.26% | -195.52% | n/a | 2.93M |
| 2022 FY Dec 31, 2021 | $115.53M | $115.53M | -$39.38M | -$10.85M | -$15.91M | 100% | -34.08% | -13.77% | n/a | 58.69M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $10.87M | sum latest 4 fiscal quarters Revenue | OK | 0001628280-26-053837, 0001628280-25-047919 |
| Revenue Growth TTM | -84.04% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001628280-26-053837, 0001628280-25-047919 |
| Revenue CAGR 3Y | 10.93% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-017019 |
| Revenue CAGR 5Y | 7.13% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001628280-26-017019 |
| Gross Profit CAGR 3Y | 10.93% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-017019 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001628280-26-053837, 0001628280-25-047919 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001628280-26-053837, 0001628280-25-047919 |
| Operating Margin | -651.21% | Operating Income / Revenue | OK | 0001628280-26-053837, 0001628280-25-047919 |
| ROIC | -1,579.33% | NOPAT / Average Invested Capital | OK | 0001628280-26-053837, 0001628280-25-047919 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001628280-26-053837 |
| Current Ratio | 12.82x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.42 | Revenue / Diluted Shares | OK | 0001628280-26-053837, 0001628280-25-047919 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |